Soluble Prion Protein Binds Isolated Low Molecular Weight Amyloid-β Oligomers Causing Cytotoxicity Inhibition

Thomas L Williams1, Jin-Kyu Choi1, Krystyna Surewicz1

  • 1Department of Physiology and Biophysics, Case Western Reserve University , Cleveland, Ohio 44106, United States.

ACS Chemical Neuroscience
|October 15, 2015
PubMed

Insights

Soluble prion protein (rPrP) prevents toxic amyloid-β (Aβ) oligomers in Alzheimer's disease by altering their size and reducing neurotoxicity. This interaction offers potential therapeutic strategies for Alzheimer's disease.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Molecular Biology

Background:

  • Soluble amyloid-β (Aβ) oligomers are implicated in Alzheimer's disease pathogenesis.
  • Cellular prion protein mediates Aβ oligomer neurotoxicity.
  • Recombinant prion protein (rPrP) can inhibit Aβ neurotoxicity, but the mechanism is unclear.

Purpose of the Study:

  • To investigate the mechanism by which rPrP interacts with and inhibits Aβ42 oligomer cytotoxicity.
  • To characterize well-defined Aβ42 oligomers and their toxic effects.

Main Methods:

  • Photoinduced cross-linking of unmodified proteins (PICUP) to isolate homogeneous Aβ42 oligomers.
  • Assessment of Aβ42 oligomer cytotoxicity on primary neurons and model lipid bilayers.
  • Evaluation of rPrP's effect on Aβ42 oligomer size distribution and toxicity.

Main Results:

  • rPrP addition shifts Aβ42 assembly towards non-toxic monomers, reducing toxic tetramers and higher-order oligomers.
  • Isolated Aβ42 oligomers exhibit size-dependent cytotoxicity and disrupt lipid bilayers.
  • rPrP effectively inhibits Aβ42-induced cytotoxicity and membrane permeation.

Conclusions:

  • rPrP modulates Aβ42 oligomerization, mitigating their neurotoxic potential.
  • Understanding the rPrP-Aβ interaction provides insight into Alzheimer's disease mechanisms.
  • This study supports the development of PrP-based therapeutics for Alzheimer's disease.